Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + DPX-Survivac + Epacadostat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|DPX-Survivac||DPX-Survivac is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (NCI Drug Dictionary).|
|Epacadostat||INCB024360||IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 95||Epacadostat (INCB024360) inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 20197554).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02785250||Phase I||Cyclophosphamide + DPX-Survivac + Epacadostat||Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer||Active, not recruiting|